- Gene2Cure Foundation has partnered with Viralgen to support the manufacturing of investigational gene therapies for rare and ultra-rare genetic diseases, initially targeting PUS3 syndrome, Smith-Lemli-Opitz syndrome and GAND.
- Viralgen will provide AAV manufacturing services through its Aava platform, including material production for toxicology studies and clinical use, depending on each program’s requirements and development stage.
Gene2Cure Foundation has partnered with contract development and manufacturing organization (CDMO) Viralgen to support the manufacturing and development of its investigational gene therapy portfolio for rare and ultra-rare genetic diseases. The collaboration will initially focus on programs targeting PUS3 syndrome, Smith-Lemli-Opitz syndrome, and GAND, conditions associated with significant unmet medical needs.
Under the agreement, Gene2Cure will use Viralgen’s proprietary Aava manufacturing platform to advance its gene therapy programs. Viralgen will provide adeno-associated virus (AAV) manufacturing services based on the requirements and development stage of each program, including production of material for toxicology studies and clinical use.
The Aava platform is designed to provide a scalable manufacturing pathway across AAV serotypes. It is intended to support gene therapy programs as they progress from preclinical research into clinical development and, potentially, commercialization.
“The partnership is intended to help advance experimental gene therapies for children with genetic conditions.”
Gene2Cure Foundation co-founder and President Prof. Leszek Lisowski
“The company will support the programs through key preclinical and clinical development stages by providing access to its Aava manufacturing platform.”
Viralgen CEO Jimmy Vanhove